Analysis of Novartis’s Q2 2026 U.S. performance, the mechanics of its patent-cliff pricing headwind, and what it signals about the company’s next growth phase
BASEL / GLOBAL BIOPHARMA DESK — If Eli Lilly’s incretin franchise shows what happens when a manufacturer chooses to compress price in pursuit of volume, Novartis’s second-quarter 2026 results show the opposite scenario: a pricing headwind imposed from the outside, as the loss of U.S. exclusivity on its former flagship product collides with genuinely strong volume-led growth from a new generation of priority brands.
At Bionext AI Market Insights, we read Novartis’s Q2 print as a company mid-transition — absorbing a scripted patent-cliff shock while proving, brand by brand, that its next growth engine is already running.
The Numbers Behind the Transition
Novartis returned to sales growth in Q2 2026, with net sales rising 1% at constant currency (3% in USD) to $14.4 billion, after a 2% constant-currency decline across the first half. The quarter’s growth decomposition is the real story for anyone tracking pricing dynamics in biopharma:
| Growth Driver | Contribution to Q2 2026 Sales Growth |
|---|---|
| Volume | +18 percentage points |
| Generic/LOE competition | -14 percentage points |
| Net pricing | -3 percentage points |
| Currency | +2 percentage points |
| Net constant-currency growth | +1% |
That -14 point generic-erosion drag is almost entirely attributable to one product: Entresto, whose U.S. patent expired in 2025. Entresto sales fell 50% year-over-year in Q2 to $1.18 billion, with Promacta and Tasigna — both facing earlier-stage U.S. generic competition — down 64% and 57%, respectively. Together, these three products account for the majority of Novartis’s reported pricing and volume erosion this year, and management estimates Entresto’s genericization alone could remove approximately $4 billion from full-year 2026 revenue.
Two Pricing Stories Running in Parallel
The erosion side of the ledger. Entresto generated $7.75 billion in 2025 — roughly 14% of total net sales — making it Novartis’s single largest product heading into its loss of exclusivity (LOE). Unlike Lilly’s voluntary price compression on Zepbound and Mounjaro, Entresto’s price decline is structural and largely non-negotiable: once generics enter, list price becomes irrelevant to the erosion curve, and net realized price falls independent of any commercial strategy. European exclusivity lapses from November 2026, meaning a second, smaller erosion wave is still ahead.
The growth side of the ledger. Offsetting that drag, Novartis’s “priority brands” grew a combined 36% at constant currency in Q2, led by:
- Kisqali (+44% USD, +43% cc): $1.695 billion in quarterly sales, crossing $1 billion in U.S. sales for the first time — a milestone driven by continued share gains in both early and metastatic breast cancer and reinforced by its NCCN Category 1 preferred status.
- Pluvicto (+43% USD, +43% cc): $651 million, powered by strong pre-taxane mCRPC demand in the U.S. and continued ex-U.S. access expansion — the clearest commercial proof point yet for Novartis’s radioligand therapy (RLT) platform.
- Kesimpta, Scemblix and Leqvio: all posting strong double-digit growth in the quarter, with Leqvio notably reaching a 23.3% share of the Medicare Part B segment, up 3.6 percentage points year-to-date — a meaningful proxy for payer-channel pricing durability in a Medicare-exposed product.
- Jakavi (+10% USD, +8% cc): $576 million, continuing steady growth across indications (note: Incyte retains U.S. rights to ruxolitinib as Jakafi).
Why the Pricing Mechanics Matter Beyond Novartis
For patent-cliff-exposed peers: Novartis’s Q2 print is a useful real-world data point on the shape of a genericization curve — a roughly 50% single-quarter revenue decline for a $7–8 billion product once U.S. generics fully enter, with a second, geographically distinct erosion event still to come in Europe. Companies modeling their own upcoming LOEs (and the analysts covering them) should treat this as a reference curve, not a worst case.
For growth-brand economics: Kisqali’s crossing of the $1 billion U.S. quarterly threshold, achieved through share gains rather than price expansion, mirrors a broader industry pattern we’re tracking: newer oncology and immunology brands are increasingly winning on clinical differentiation and guideline-preferred status rather than on price, a dynamic that should make their revenue trajectories more resilient to future payer pressure than the products they’re replacing.
For Medicare-exposed portfolios: Leqvio’s expanding Part B share is an early signal of how government-payer channels are behaving for newer, higher-cost specialty therapies post-Inflation Reduction Act — worth watching alongside Lilly’s own Medicare Bridge exposure in obesity care as a bellwether for how CMS channels are reshaping net pricing across categories.
For portfolio construction: The net effect — a company posting essentially flat headline growth while simultaneously absorbing a ~$4 billion single-product erosion event and growing five other brands at double-to-triple-digit rates — illustrates why headline net sales figures alone understate the underlying commercial momentum in a story like Novartis’s this year.
BioNext AI Market Insights View
We see Novartis’s Q2 2026 results as confirmation that its post-Entresto transition is proceeding roughly on management’s own script, not as evidence of underlying commercial weakness. The -3 point net pricing headwind is modest set against the -14 point generic-competition drag, suggesting the erosion is a one-time structural event rather than a broader loss of pricing power across the portfolio. With management guiding to mid-single-digit net sales growth in the second half as year-over-year Entresto comparisons ease, and priority brands still compounding at high double-digit rates, the more important question for H2 and into 2027 is less about Entresto and more about durability: whether Kisqali, Pluvicto, and the radioligand therapy platform can scale into the multi-billion-dollar franchises needed to fully replace what Entresto, Cosentyx-era exclusivity, and other maturing assets will contribute progressively less of through the remainder of Novartis’s 2025–2028 patent-cliff window.
About Bionext AI Market Insights Bionext AI Market Insights delivers data-driven intelligence on biopharma commercial strategy, market access, and competitive dynamics for investors, strategy teams, and industry stakeholders.
This analysis is based on publicly available company disclosures, regulatory filings, and third-party reporting current as of publication. It does not constitute investment advice. Figures cited are sourced from Novartis AG’s public financial disclosures for Q2 2026 (period ended June 30, 2026) and are subject to revision upon subsequent reporting.
By
